<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593722</url>
  </required_header>
  <id_info>
    <org_study_id>999912117</org_study_id>
    <secondary_id>12-I-N117</secondary_id>
    <nct_id>NCT01593722</nct_id>
  </id_info>
  <brief_title>Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis</brief_title>
  <official_title>Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Loa loa is a small worm that infects people in West and Central Africa. It is spread by
           the bite of a fly. Adult worms live under the skin and can cause swelling in the arms,
           legs, and face. Some people have more serious infections in the heart, kidneys, or
           brain. Most people with Loa loa infection have no symptoms at all. The standard
           treatment for Loa loa infection is a medicine called diethylcarbamazine (DEC). Some
           people have bad reactions to DEC, including itching, muscle pains, and in severe cases
           coma and death.

        -  Another drug, ivermectin, is used in mass drug treatment programs to prevent the spread
           of worm infections that cause blindness and massive swelling (elephantiasis). However,
           people who also have Loa loa have had serious bad reactions to ivermectin. Researchers
           want to study both DEC and ivermectin to find out why these reactions occur. If they can
           be prevented, mass drug treatment programs will be able to be used in areas in Africa
           where Loa loa exists.

      Objectives:

      - To study the side effects of DEC and ivermectin treatment for Loa loa infection.

      Eligibility:

      - Individuals who live in 4 villages in Cameroon where Loa loa infection is known to exist,
      who are between 20 and 60 years of age, not pregnant or breastfeeding and have a low level of
      Loa loa parasites in the blood, but are otherwise healthy.

      Design:

        -  Participants will be screened with a physical exam and medical history. Blood samples
           will be collected to check for Loa loa infection. Participants will also have an eye
           exam and provide skin samples to check for other worm infections that may interfere with
           the study treatment.

        -  Participants will be admitted to the hospital for 4 days (during and after the
           treatment). They will receive a single dose of either DEC or ivermectin.

        -  After treatment, regular blood samples will be collected. Participants will be asked
           questions about how they feel after treatment. Physical exams will be performed. If side
           effects develop, participants will be treated at the hospital.

        -  After leaving the hospital, participants will have followup visits. These visits will
           happen on days 5, 7, 9, and 14 after receiving the study medicine. They will involve a
           short physical exam and collection of blood samples.

        -  At the end of the study, participants will be offered a full 21-day DEC treatment to
           cure the Loa loa infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ivermectin is currently used for mass drug distribution for the control of onchocerciasis and
      elimination of lymphatic filariasis in Africa. Due to the occurrence of severe neurologic
      adverse events in individuals with concomitant Loa loa infection and high levels of
      circulating microfilariae, drug distribution has been halted in many areas in Cameroon,
      Democratic Republic of Congo and other Loa-endemic countries. Diethylcarbamazine citrate
      (DEC) is the treatment of choice for Loa loa infection in the United States and other
      non-endemic countries, but can also be associated with the development of severe adverse
      reactions, including fatal encephalopathy, that are correlated with the number of circulating
      microfilariae in the blood. The cause of these reactions is unknown, and it is not known if
      post-treatment reactions to DEC and ivermectin both have the same underlying mechanism.
      Post-treatment reactions to both medications are accompanied by a dramatic interleukin-5
      (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. Preliminary
      data suggests that, unlike post-treatment responses in Wolbachia-containing filariae,
      inflammatory mediators commonly seen in bacterial infections and malaria, including tumor
      necrosis factor (TNF)-alpha and IL-1-beta, are not increased post-treatment with DEC. The aim
      of this study is to characterize the immunologic mechanisms of ivermectin and DEC
      posttreatment reactions so that it can be established whether or not these posttreatment
      reactions have the same underlying mechanism. An understanding of the pathophysiology of
      these post-treatment reactions is necessary in order to develop strategies to prevent these
      reactions in the future. We plan to randomize 20 subjects with low- to- moderate numbers of
      circulating Loa loa microfilariae to receive a single oral dose of either ivermectin (200
      mcg/kg) or DEC (8 mg/kg) in an inpatient setting in Cameroon. Signs and symptoms, blood
      microfilarial levels, complete blood counts, intracellular and serum cytokine levels and
      markers of eosinophil activation will be assessed at baseline, 4 and 8 hours, and 1, 2, 3, 5,
      7, and 9 and 14 days post-treatment and compared between the two treatment groups. Subjects
      who received ivermectin will be treated with single dose DEC (8 mg/kg) on day 14. All
      subjects will then be followed at 6 and 12 months post-hospitalization to determine whether
      they have experienced Loa-specific symptoms (eyeworm or Calabar swellings). Mf count and
      complete blood count (CBC) with differential will be obtained at each follow-up visit.
      Subjects with Loa-specific symptoms or mf counts &gt; 100 mf/mL at the 6 month time point will
      be offered a full treatment course. If &gt; 50% of subjects meet criteria for full DEC treatment
      at the 6, month time point, all subjects will be treated and the study will enter a follow-up
      phase with a visit at 12 months (6 months after the full treatment course ).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Frequency of Adverse Events</measure>
    <time_frame>7 days</time_frame>
    <description>Symptoms, signs and laboratory abnormalities occurring in the 7 days post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil Activation</measure>
    <time_frame>3 days</time_frame>
    <description>Levels of surface marker expression on eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Clear Microfilaremia</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment Efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects without signs of infection</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Loiasis</condition>
  <arm_group>
    <arm_group_label>diethylcarbamazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diethylcarbamazine 8 mg/kg single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ivermectin 200 mcg/kg single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylcarbamazine</intervention_name>
    <description>single dose</description>
    <arm_group_label>diethylcarbamazine</arm_group_label>
    <other_name>Hetrazan, Banocide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>single dose</description>
    <arm_group_label>ivermectin</arm_group_label>
    <other_name>Mectizan, Stromectol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA (SCREENING):

        A subject will be eligible for participation in the screening portion of this protocol if
        all of the following criteria apply:

          1. male or non-pregnant and not breastfeeding female subjects,

          2. age 20-60 years (per participant self-report)

          3. resident of Akonolinga

          4. Loa microfilaremia from 20 to 5000 mf/mL from the prior screening in the village or
             did not participate in the prior screening

          5. consent to a blood draw to screen for infection with Loa loa

          6. must be willing to have blood samples stored

        EXCLUSION CRITERIA (SCREENING):

        A subject will not be eligible for participation in the screening portion of this study if
        any of the following conditions apply:

          1. Known to be pregnant (by history) or breastfeeding

          2. Chronic medical conditions, including but not limited to diabetes, renal or hepatic
             insufficiency, immunodeficiency, psychiatric disorder, seizure, that in the
             investigators judgments are deemed to be clinically significant

          3. History of hypersensitivity reaction to DEC or IVM

        INCLUSION CRITERIA (INTERVENTIONAL STUDY):

        A subject will be eligible for participation in the interventional portion of the study
        only if all of the following additional inclusion criteria apply:

          1. Loa loa microfilaremia between 20 and 2,000 mf/mL blood drawn between 11:30 am and
             2:30 pm measured within 30 days prior to the baseline visit

          2. The subject agrees to storage of samples for study

        EXCLUSION CRITERIA (INTERVENTIONAL STUDY):

        A subject will not be eligible to participate in the interventional portion of the study if
        any of the following conditions are fulfilled at the time of enrollment:

          1. Pregnancy (by serum or urine beta-HCG) or breastfeeding

          2. Chronic kidney or liver disease

          3. Hgb &lt; 10 gm/dL

          4. Filarial infection other than Loa loa or M. perstans (O. volvulus, or W. bancrofti)

          5. Use of DEC or IVM within the past 6 months

          6. Use of immunosuppressive therapies, including steroids, within the past month

          7. Any condition that in the investigator s opinion places the subject at undue risk by
             participating in the study

        EXCLUSION OF CHILDREN AND PREGNANT WOMEN:

        Pregnant women and children (the age of consent in Cameroon is 20 years of age) will be
        excluded from this study since it involves administration of medications contraindicated in
        pregnancy and more than minimal risk with no prospect of direct benefit, respectively.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy D Klion, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Filariasis and other Tropical Diseases Research Center</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <reference>
    <citation>Klion AD, Massougbodji A, Sadeler BC, Ottesen EA, Nutman TB. Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. J Infect Dis. 1991 Jun;163(6):1318-25.</citation>
    <PMID>2037798</PMID>
  </reference>
  <reference>
    <citation>Boussinesq M. Loiasis. Ann Trop Med Parasitol. 2006 Dec;100(8):715-31. Review.</citation>
    <PMID>17227650</PMID>
  </reference>
  <reference>
    <citation>Winkler S, Paiha S, Winkler H, Graninger W, Marberger M, Steiner GE. Microfilarial clearance in loiasis involves elevation of Th1 and Th2 products and emergence of a specific pattern of T-cell populations. Parasite Immunol. 1996 Sep;18(9):479-82.</citation>
    <PMID>9226684</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2012</study_first_submitted>
  <study_first_submitted_qc>May 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <results_first_submitted>December 2, 2015</results_first_submitted>
  <results_first_submitted_qc>September 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2016</results_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loa loa</keyword>
  <keyword>Immune Response</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Diethylcarbamazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of the155 subjects recruited, 92 were eligible for screening and signed consent. Thirty had loiasis, of which 16 were excluded because their microfilarial counts were &gt;5000 mf/mL. One subject was excluded because of age and one declined to participate. The remaining 12 patients were enrolled in the treatment arm of the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Dose DEC</title>
          <description>diethylcarbamazine 8 mg/kg single oral dose
Diethylcarbamazine: single dose</description>
        </group>
        <group group_id="P2">
          <title>Single Dose IVM</title>
          <description>ivermectin 200 mcg/kg single oral dose
Ivermectin: single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Dose DEC</title>
          <description>diethylcarbamazine 8 mg/kg single oral dose
Diethylcarbamazine: single dose</description>
        </group>
        <group group_id="B2">
          <title>SIngle Dose IVM</title>
          <description>ivermectin 200 mcg/kg single oral dose
Ivermectin: single dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" lower_limit="20" upper_limit="60"/>
                    <measurement group_id="B2" value="38.5" lower_limit="25" upper_limit="53"/>
                    <measurement group_id="B3" value="44.5" lower_limit="20" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cameroon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Absolute eosinophil count</title>
          <units>cells x 10^9/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.27" lower_limit="2.3" upper_limit="5.76"/>
                    <measurement group_id="B2" value="1.76" lower_limit="1.05" upper_limit="2.35"/>
                    <measurement group_id="B3" value="2.40" lower_limit="1.05" upper_limit="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Loa microfilarial count</title>
          <units>mf/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1074" lower_limit="200" upper_limit="20380"/>
                    <measurement group_id="B2" value="355" lower_limit="60" upper_limit="2300"/>
                    <measurement group_id="B3" value="618" lower_limit="60" upper_limit="20380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment.</title>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diethylcarbamazine</title>
            <description>diethylcarbamazine 8 mg/kg single oral dose
Diethylcarbamazine: single dose</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin</title>
            <description>ivermectin 200 mcg/kg single oral dose
Ivermectin: single dose</description>
          </group>
        </group_list>
        <measure>
          <title>The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment.</title>
          <units>percentage of baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" lower_limit="112" upper_limit="224"/>
                    <measurement group_id="O2" value="165" lower_limit="124" upper_limit="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Frequency of Adverse Events</title>
        <description>Symptoms, signs and laboratory abnormalities occurring in the 7 days post-treatment</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diethylcarbamazine</title>
            <description>diethylcarbamazine 8 mg/kg single oral dose
Diethylcarbamazine: single dose</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin</title>
            <description>ivermectin 200 mcg/kg single oral dose
Ivermectin: single dose</description>
          </group>
        </group_list>
        <measure>
          <title>The Frequency of Adverse Events</title>
          <description>Symptoms, signs and laboratory abnormalities occurring in the 7 days post-treatment</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophil Activation</title>
        <description>Levels of surface marker expression on eosinophils</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose DEC</title>
            <description>diethylcarbamazine 8 mg/kg single oral dose
Diethylcarbamazine: single dose</description>
          </group>
          <group group_id="O2">
            <title>Single Dose IVM</title>
            <description>ivermectin 200 mcg/kg single oral dose
Ivermectin: single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophil Activation</title>
          <description>Levels of surface marker expression on eosinophils</description>
          <units>% cells expressing CD69</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>%CD69 expression on eosinophils at peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" lower_limit="6.1" upper_limit="79.7"/>
                    <measurement group_id="O2" value="21.5" lower_limit="8.4" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%CD69 expression on eosinophils at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.1" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.1" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Clear Microfilaremia</title>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diethylcarbamazine</title>
            <description>diethylcarbamazine 8 mg/kg single oral dose
Diethylcarbamazine: single dose</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin</title>
            <description>ivermectin 200 mcg/kg single oral dose
Ivermectin: single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Clear Microfilaremia</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Treatment Efficacy</title>
        <description>Proportion of subjects without signs of infection</description>
        <time_frame>6 months</time_frame>
        <population>Microfilarial count and symptoms</population>
        <group_list>
          <group group_id="O1">
            <title>Diethylcarbamazine</title>
            <description>diethylcarbamazine 8 mg/kg single oral dose
Diethylcarbamazine: single dose</description>
          </group>
          <group group_id="O2">
            <title>Ivermectin</title>
            <description>ivermectin 200 mcg/kg single oral dose
Ivermectin: single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Efficacy</title>
          <description>Proportion of subjects without signs of infection</description>
          <population>Microfilarial count and symptoms</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diethylcarbamazine</title>
          <description>diethylcarbamazine 8 mg/kg single oral dose
Diethylcarbamazine: single dose</description>
        </group>
        <group group_id="E2">
          <title>Ivermectin</title>
          <description>ivermectin 200 mcg/kg single oral dose
Ivermectin: single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eyeworm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia/arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Calabar swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Amy Klion</name_or_title>
      <organization>Laboratory of Parasitic Diseases, NIAID, NIH</organization>
      <phone>301-435-8903</phone>
      <email>aklion@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

